论文部分内容阅读
应用１３１Ｉ－ＭＧ７对９例胃癌病人行内镜下癌内多点注射法放射免疫治疗（ＲＩＴ），另两例仅以１３１Ｉ－ＮａＩ胃癌内注射作为对照。注射后应用ＳＰＥＣＴ对放射免疫显像（ＲＩ）行系列观察。ＲＩ满意组５例中胃癌区均见放射性浓聚，以癌性溃疡区最浓，Ｔ／ＮＴ比值高，平均２．３６～１１．１６，维持８～１７天以上。治疗后１～２月癌组织活检病理复查有明显的放射效应，已达到了ＲＩＴ内放射治疗的要求和目的，说明内镜下胃癌内注射１３１Ｉ－ＭＧ７ＲＩＴ具有临床应用前景。１３１Ｉ剂量偏小以及１３１Ｉ－ＭＧ７在胃癌内扩散分布尚不均匀一致是今后需要改进的问题
Nine patients with gastric cancer were treated with 131I-MG7 using endoscopic intratumoral multipoint injection radioimmunotherapy (RIT), and the other two patients were treated with 131I-NaI intragastric injection alone as a control. SPECT was used for radioimmunotherapy (RI) after injection. In the RI-satisfactory group, radioactivity concentration was found in 5 cases of gastric cancer, with the most concentrated cancerous area, and a high T/NT ratio (average 2.36 to 11.16) for 8 to 17 days. After 1 to 2 months of treatment, the pathological review of cancer biopsy showed significant radiological effects, which had met the requirements and goals of radiotherapy in RIT. It was demonstrated that intra-tumor injection of 131I-MG7RIT has clinical application prospects. The small dose of 131I and the uneven distribution of 131I-MG7 in gastric cancer are consistent and need to be improved in the future.